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concentration was significantly correlated with the estimat-
ed glomerular filtration rate (eGFR) (r = 0.4, p  ! 0.001). In mul-
tivariate analysis, eGFR, serum ferritin, age, gender, time 
since transplantation and centres were independently and 
significantly associated with Hb. Only 24% of the patients 
who had a Hb concentration  ! 110 g/l were treated with an 
erythropoiesis-stimulating agent. The prevalence of anae-
mia and also the use of erythropoiesis-stimulating agents 
were significantly different across the different centres, sug-
gesting substantial practice variations.  Conclusions: PTA is 
still common and under-treated. The prevalence and man-
agement of PTA have not changed substantially since the 
TRESAM survey.  Copyright © 2010 S. Karger AG, Basel 
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 Abstract 
 Background: Although it is a known predictor of mortality, 
there is a relative lack of recent information about anaemia 
in kidney transplant recipients. Thus, we now report data 
about the prevalence and management of post-transplant 
anaemia (PTA) in Europe 5 years after the TRansplant Eu-
ropean Survey on Anemia Management (TRESAM) study. 
 Methods: In a cross-sectional study enrolling the largest 
number of patients to date, data were obtained from 5,834 
patients followed at 10 outpatient transplant clinics in four 
European countries using the American Society of Trans-
plantation anaemia guideline.  Results: More than one third 
(42%) of the patients were anaemic. The haemoglobin (Hb) 
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 Introduction 
 Complications of chronic kidney disease (CKD), such 
as anaemia, are present in a substantial proportion of kid-
ney transplant (RTx) recipients and have a negative im-
pact on clinical outcomes  [1] . Post-transplant anaemia 
(PTA) is common  [2–8] , with a consistent prevalence of 
30–40%  [3, 5, 6] . The estimated prevalence of severe anae-
mia, potentially requiring treatment based on current 
guidelines, is 10–15%  [3, 5] . In 2003, the TRESAM study 
(TRansplant European Survey on Anemia Management) 
collected data about PTA from centres across Europe  [5] .
 Renal anaemia is effectively treated with erythropoie-
sis-stimulating agents (ESAs). Treatment benefits include 
improvement in quality of life, symptom relief  [9] and 
possibly cardiovascular protection  [10] , although not all 
studies have confirmed this  [11] . The DOPPS (Dialysis 
Outcomes and Practice Patterns Study) trial showed large 
international variations in anaemia management in pa-
tients on maintenance dialysis  [12] , but the practice pat-
terns of PTA treatment have not been previously studied 
in detail.
 Anaemia is associated with early post-transplant car-
diovascular risk in RTx recipients  [10, 13, 14] . Winkelmay-
er at al.  [15] found no association between anaemia or hae-
moglobin (Hb) level and outcome. We and others, on the 
other hand, have demonstrated that anaemia was indepen-
dently associated with mortality and graft failure  [1, 16] .
 We expected that the prevalence of PTA has decreased 
and the treatment of PTA has become more consistent 
since the TRESAM study. To test this hypothesis, we ob-
tained a cross-sectional dataset of 5,834 patients from 10 
renal transplant units across Europe. We found that the 
prevalence and management practices related to PTA are 
quite variable and overall have remained largely un-
changed over the last 5 years.
 Subjects and Methods 
 Patients and Data Collection 
 This cross-sectional study used a descriptive correlational de-
sign. A convenience sample of 10 transplant centres from 4 Euro-
pean countries was selected. Exclusion criteria for individual pa-
tients were multiple organ transplantation, pregnancy at the time 
of enrolment, age  ! 18 years at the time of enrolment and  ! 3 
months since transplant.
 Demographic and laboratory data were extracted from the 
electronic databases of the participating centres. The following 
laboratory parameters were tabulated: Hb, serum creatinine, 
blood urea nitrogen and serum ferritin. Transplant-related data 
extracted from the medical records included the use of ESA and 
transplant ‘vintage’, i.e. time elapsed since the time of the trans-
plantation. This was divided into five categories to facilitate anal-
ysis:  ! 6 months, 6 months–1 year, 1–3 years, 3–5 years and  1 5 
years. Estimated glomerular filtration rate (eGFR) was calculated 
using the abbreviated Modification of Diet in Renal Disease 
(MDRD) study formula  [17] .
 Definition of Anaemia and Iron Deficiency 
 We used two anaemia definitions in our analyses. First, anae-
mia was defined according to the anaemia guideline of the Amer-
ican Society of Transplantation (AST): Hb  ! 130 g/l in adult males 
and 120 g/l in adult females  [18] . In this work we used this defini-
tion unless stated otherwise. Anaemic patients were subsequently 
divided into three sub-categories to gauge severity: (I)  mild: 
males: 120  ! Hb  ^  130 g/l; females: 110  ! Hb  ^  120 g/l; (II)  mod-
erate (as anaemia defined by the NKF-K/DOQI  [19] ): males: 110 
 ! Hb  ^  120 g/l; females: 100  ! Hb  ^  110 g/l, and (III)  severe: 
males: Hb  ^  110 g/l; females: Hb  ^  100 g/l.
 Second, the data were re-analyzed using a cut-off value of Hb 
 ! 110 g/l that is suggested to trigger treatment with ESAs in pa-
tients with CKD, including kidney-transplanted patients, by cur-
rent guidelines  [19–21] . 
 Iron deficiency was defined as a serum ferritin level  ! 100
ng/ml.
 Statistical Analysis 
 Statistical analysis was carried out using the SPSS 15.0 soft-
ware. Continuous variables were compared using Student’s t test 
or the Mann-Whitney U test, and categorical variables were ana-
lyzed with the   2 test. ANOVA testing with Bonferroni correction 
for multiple comparisons was used to analyze the relationship be-
tween continuous variables. Bivariate analysis was performed us-
ing the Pearson or Spearman correlation analysis as appropriate. 
For multivariate analysis linear or logistic regression was used, 
centres were analyzed as dummy variables. 
 Results 
 Demographics and Baseline Characteristics of the 
Sample 
 The study population included 5,834 patients; the 
mean age was 50  8 14 years, 62% were males. Baseline 
patient characteristics are shown in  table 1 . The median 
(interquartile range) time since transplantation was 85 
(106) months.
 The mean age of the sub-cohorts increased signifi-
cantly with increasing transplant vintage ( table 1 ). The 
eGFR showed a decreasing trend across the five sub-co-
horts formed according to transplant vintage.
 Prevalence of Anaemia  
 Mean Hb for the total sample was 129  8 17 g/l. Based 
on the AST criteria, overall 42% of the patients were anae-
mic ( table 1 ). Furthermore, 18% of the total sample had 
mild, 15% had moderate and 9% had severe anaemia. 
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 818 (14%) of the patients had Hb levels  ! 110 g/l. The 
proportion of female patients with a Hb level  ! 110 g/l was 
significantly higher than the proportion of males with a 
similar Hb level (20 vs. 11%; p  ! 0.001).
 Iron Deficiency  
 Serum ferritin was available for 3,352 of the patients, 
47% of whom had a level  ! 100 ng/ml. Significantly more 
female patients had serum ferritin levels  ! 100 ng/ml than 
males (50 vs. 44%; p  ! 0.001). The average serum ferritin 
level showed a strongly decreasing trend with increasing 
vintage of the sub-cohorts ( table 1 ). Serum ferritin showed 
a weak negative correlation with Hb (R = –0.102; p  ! 
0.001) and eGFR (R = –0.145; p  ! 0.001).
 Correlates of Anaemia  
 Age did not show a clinically meaningful correlation 
with Hb levels (R = 0.029; p  ! 0.05). Female transplant 
recipients had significantly lower mean Hb than males 
(females 123  8 15 g/l; males 133  8 17 g/l; p  ! 0.001), and 
female gender was significantly associated with the prev-
alence of anaemia except when using the AST criteria of 
anaemia which are gender-specific.
 eGFR correlated significantly with Hb in the total sam-
ple (R = 0.4; p  ! 0.001). Approximately one fourth of the 
patients (23%) had an eGFR  6 60 ml/min/1.73 m 2 (group 
1). eGFR was 30–60 ml/min/1.73 m 2 in 59% of the patients 
(group 2) and it was  ! 30 ml/min/1.73 m 2 in 18% (group 
3). The mean Hb levels in the groups defined by eGFR 
were: 137  8 15, 129  8 16 and 116  8 16 g/l for groups 1, 
2 and 3, respectively (p  ! 0.001), and we found a similar 
trend between the prevalence of anaemia and CKD stages 
( fig.  1 ). eGFR correlated significantly with Hb both in 
group 2 (R = 0.250; p  ! 0.001) and in group 3 (R = 0.236; 
p  ! 0.001), i.e. in CKD stages 3–5. No association was seen 
between Hb and eGFR in group 1, i.e. CKD stage 1–2.
 Additionally, we re-analyzed our data for CKD stage 
3a (59–45 ml/min/1.73 m 2 ) and CKD stage 3b (44–30 ml/
min/1.73 m 2 )  [22] . eGFR correlated significantly with Hb 
in both sub-groups: CKD 3a (R = 0.099; p  ! 0.001) and 
CKD 3b (R = 0.136; p  ! 0.001). The prevalence of anaemia 
was 34 and 50% for CKD3a and CKD3b, respectively 
( fig. 1 ).
Table 1. P atients’ characteristics
Time since transplantation Total population
(n = 5,834)
<6 months
(n = 56)
6 months–1 year
(n = 246)
1–3 years
(n = 913)
3–5 years
(n = 893)
>5 years
(n = 3,726)
p
value
Mean age 8 SD, years 50814 45813 46813 47814 48814 51814 <0.001
Gender, male, % 62 64 62 64 63 61 NS*
Mean Hb 8 SD, g/l 129817 120818 129818 129817 130817 128817 <0.001
Mean eGFR 8 SD, ml/min/1.73 m2 47819 50820 50816 51819 48819 46820 <0.001
Ferritin, ng/ml
Median 114 315 198 144 134 94 <0.001
Interquartile range 219 396 482 285 273 184
Anaemia based on AST definition, % 42 59 44 42 36 44 NS*
Anaemia based on Hb <110 g/l, % 14 29 15 14 12 14 NS*
ESA use, % 11 18 17 15 11 10 <0.001*
* p value: linear-by-linear association.
Table 2. L inear regression model of Hb as the dependent variable 
(adjusted R2: 28%, p < 0.001)
Level of
significance
t 
Age <0.001 7.241 0.110
Gender (female) <0.001 –15.670 –0.232
eGFR <0.001 22.946 0.349
Serum ferritin <0.001 –5.062 –0.078
Time since transplantation <0.001 –3.886 –0.060
Centre ‘J’ (ref.)
Centre ‘H’
Centre ‘G’
Centre ‘F’
Centre ‘E’
Centre ‘D’
Centre ‘B’
Centre ‘A’
–
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
–3.598
–3.554
–4.711
–5.430
–14.054
–9.273
–6.265
–0.071
–0.057
–0.072
–0.106
–0.268
–0.184
–0.093
R eference centre was Centre ‘J’ (as dummy variable), because 
in our sample, the prevalence of anaemia was the lowest there. 
From Centre ‘C’ and ‘I’ some variables are missing; consequently, 
patients from these centres are not included in this analysis.
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 Transplant vintage is reportedly associated with Hb  [5, 
23] . In our sample the mean Hb was significantly lower 
in sub-cohort 1 (i.e. within 6 months of transplantation) 
compared to the remaining sub-cohorts ( table 1 ).
 Multivariate Analysis 
 Multivariable linear regression analysis was used to 
identify independent predictors of Hb. In this model (ad-
justed R 2 = 0.28, p  ! 0.001), age, gender, eGFR, serum fer-
ritin, time since transplantation and centres were all in-
dependently associated with the Hb concentration ( ta-
ble 2 ). Qualitatively similar results were found in logistic 
regression models where the presence of anaemia (by 
each definition) was used as a dependent variable (results 
not shown).
 Anaemia Treatment 
 An ESA was used in 11% of the total sample and in 17% 
of anaemic (by AST definition) patients. Anaemic pa-
tients receiving ESA therapy had a lower mean Hb (109 
 8 12 vs. 114  8 10 g/l; p  ! 0.001) and eGFR (30  8 15 vs. 
42  8 18 ml/min/1.73 m 2 ; p  ! 0.001) than anaemic pa-
tients not receiving ESA. The percentage of ESA use in-
creased with CKD stages ( fig. 2 ). ESA was given to 13% of 
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 Fig. 1. Prevalence of anaemia and CKD stages in kidney-trans-
planted patients. 
 Fig. 2. ESA therapy and CKD stages in kidney-transplanted pa-
tients. 
 Fig. 3. Prevalence of anaemia (based on 
AST definition) and proportion of ESA 
therapy in patients with Hb  ! 110 g/l in the 
different centres. 
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the mildly, 15% of the moderately and 28% of the severe-
ly anaemic patients (p  ! 0.001). 76% of the patients with 
Hb levels  ! 110 g/l and 67% of the patients with Hb  ! 100 
g/l were not treated with ESA. ESA use was also different 
according to transplant vintage ( table 1 ). Finally, 2.6% of 
the patients with Hb  1 130 g/l were prescribed ESA ther-
apy.
 Anaemia Prevalence and Treatment by Centre 
 The number of patients were 87 in centre ‘A’, 1,535 in 
centre ‘B’, 571 in centre ‘C’, 673 in centre ‘D’, 537 in centre 
‘E’, 341 in centre ‘F’, 140 in centre ‘G’, 809 in centre ‘H’, 
554 in centre ‘I’, and 587 in centre ‘J’.
 The average Hb level was significantly different in the 
different centres (p  ! 0.001). The highest mean Hb level 
was 134  8 17 g/l (centre ‘J’) and the lowest 121  8 19 g/l 
(centre ‘D’). The prevalence of anaemia was the lowest 
also in centre ‘J’ (28%) and the highest in centre ‘D’ (59%) 
( fig.  3 ). Similar results were found when the different 
anaemia definitions were used, suggesting differences in 
management practice.
 The average eGFR was also significantly different be-
tween the centres (p  ! 0.001). The highest mean eGFR (56 
 8 23 ml/min/1.73 m 2 ) was seen in centre ‘A’ and the low-
est (43  8 17 ml/min/1.73 m 2 ) in centre ‘I’. Serum ferritin 
level was also different between centres.
 The use of ESA therapy was also significantly different 
across the centres and ranged from 3% of the total patient 
population in centre ‘A’ to 22% in centre ‘H’. Similarly, the 
proportion of ESA therapy in patients with Hb  ! 110 g/l 
was also different in centres ( fig. 3 ). 10% of the patients 
with Hb  ! 110 g/l were treated with ESA at centre ‘A’ (the 
lowest) and 46% of similar patients were receiving ESA at 
centre ‘G’ (the highest). Of the patients with Hb  1 130 g/l, 
the range treated with ESA therapy was 0–17%.
 Discussion 
 In this study we have demonstrated that the preva-
lence of PTA remains high and similar to what had been 
reported 5 years ago in the TRESAM study. The propor-
tion of anaemic patients was 42% in this dataset (it was 
39% in TRESAM). Eleven percent of the patients in this 
dataset were treated with ESA (5% in TRESAM)  [5] . Fur-
thermore, similar to the findings in TRESAM, more than 
two thirds of the patients with Hb  ! 110 g/l had not been 
receiving ESA treatment. We also demonstrated that sub-
stantial practice variations exist in the anaemia manage-
ment among different European centres. Most of our pa-
tients had received their transplant more than 1 year pri-
or to their enrolment in our survey; consequently, these 
results are applicable to this sub-group of RTx patients.
 The severity of anaemia in this cohort was also similar 
to the findings of the TRESAM survey  [5] . Variable defi-
nitions of PTA are used in the literature  [24] . Our pri-
mary anaemia definition is based on the anaemia guide-
line of the AST  [3, 5, 6] . To have a definition that could 
potentially affect patient care, we also used a cut-off val-
ue of 110 g/l which is suggested to trigger treatment with 
an ESA in patients with CKD  [4, 19, 25] . The prevalence 
of this anaemia in this dataset was about half of the prev-
alence reported by Winkelmayer et al.  [4] , but it is similar 
to the prevalence found by Yorgin et al.  [25] in 2002. Dif-
ferent case mix, variable immunosuppressive protocols 
and ESA utilization may in part explain these substan-
tially different results. It is important to emphasize that 
about 76% of the patients with Hb  ! 110 g/l (67% of those 
with Hb  ! 100 g/l) did not receive ESA treatment.
 Although iron deficiency is one of the potential causes 
of PTA, it has rarely been analyzed in this context. Mix 
et al.  [26] found that iron stores were checked in only 12% 
of their 240 patients. The best measure to assess iron de-
ficiency would be the percentage of hypochromic red 
blood cells  [27] . In this survey we did not have appropri-
ate information about the iron status for more than one 
third of the enrolled patients. The observed negative cor-
relation between serum ferritin and Hb is almost certain-
ly due to the fact that serum ferritin is profoundly influ-
enced by other factors, particularly by inflammation.
 In contrast to previous results  [3] , we found a weak
and clinically not meaningful correlation between age 
and Hb. Although the prevalence of anaemia by the AST 
definition was similar in males and females, the mean Hb 
concentration was significantly lower in females, simi-
larly to previous results  [3, 5] . Our results suggest that 
women are more at risk of developing severe anaemia po-
tentially requiring treatment.
 The eGFR was the strongest correlate of Hb levels even 
after controlling for covariables  [3, 5, 6, 25] . Interestingly, 
however, this association was not seen in one fifth of the 
patients who had eGFR  1 60 ml/min/1.73 m 2 . This sug-
gests that PTA develops only after a substantial reduction 
in eGFR occurred. In the majority of the population the 
prevalence of anaemia showed a marked increase with 
declining renal function, similarly to what had been
reported by Karthikeyan et al.  [28] . Importantly, this
association was already significant in CKD stage 3a. Fur-
thermore, the prevalence of anaemia in CKD3a was sig-
nificantly higher than in patients with CKD1 and 2. 
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These results suggest that even modest reductions in re-
nal function below the threshold of eGFR of 60 ml/
min/1.73 m 2 have a significant impact on Hb level. The 
prevalence of anaemia in patients with significantly re-
duced eGFR was similar to that seen in CKD patients not 
yet requiring renal replacement therapy  [29] .
 In the total study sample, 17% of the anaemic patients 
received an ESA. This proportion was higher than previ-
ous results  [5, 25, 26] . The European Best Practice Guide-
line for the management of transplanted patients suggests 
that ESA therapy should be considered when Hb is con-
sistently  ! 110 g/l. Even in this group, only 24% of the pa-
tients were treated with ESA, which seems low given the 
fact that cardiorenal anaemia syndrome is a known risk 
factor  [30] and PTA is reportedly associated with mortal-
ity  [1, 16] .
 Recent reports of prospective randomized studies test-
ing the effect of ESAs in patients with CKD (the CHOIR, 
CREATE and TREAT studies) have suggested that tar-
geting patients with CKD and renal anaemia to reach 
normal or close normal Hb levels with the use of ESAs 
does not confer survival benefit or even substantial im-
provement in health-related quality of life  [11, 31, 32] . 
Concern about the potential risk of such treatment strat-
egies has been raised. Furthermore, in a recent retrospec-
tive analysis of more than 1,700 RTx recipients, Heinze et 
al.  [16] showed significantly increased mortality in pa-
tients who received ESA and had Hb  1 125–140 g/l. Im-
portantly, however, the lowest mortality risk in patients 
receiving ESA was at Hb 125 g/l  [16] . Furthermore, pa-
tients who did not receive ESA but had Hb  1 125 g/l had 
even a lower mortality risk. Finally, in an analysis of data 
from about 900 prevalent RTx recipients, we found that 
the use of ESA was not associated with increased mortal-
ity after controlling for Hb and serum erythropoietin lev-
els in addition to sociodemographic and clinical variables 
 [33] .
 Based on these results it is difficult to conclude what 
the optimal target for Hb level should be. The current 
guidelines, which suggest to initiate ESA treatment if Hb 
is consistently  ! 110 g/l and maintain Hb between 110 and 
120 g/l, seem to be safe. Appropriate large-scale prospec-
tive studies to define the role and targets for ESA therapy 
in RTx patients are needed.
 Irrespective of the specific questions discussed above, 
we suggest that PTA still needs special attention. PTA has 
been repeatedly shown to be associated with an increased 
risk of mortality  [1] . It appears from all the results briefly 
summarized above that the presence of PTA (and renal 
anaemia in patients with non-transplant CKD) is a mark-
er of underlying processes and conditions (likely involv-
ing protein-energy wasting and others) eventually lead-
ing to poor clinical outcome. Even if increasing Hb with 
the use of ESAs in patients with moderately reduced Hb 
may not be needed, those patients will still need focused 
attention to identify any potential modifiable factors 
causing their anaemia and also to optimize the manage-
ment of other potentially modifiable cardiovascular risk 
factors.
 In the multivariate analysis, the ‘centre’ was indepen-
dently associated with anaemia and Hb even after con-
trolling for several covariables. In addition to potentially 
variable comorbidity (which we did not have information 
about) and immunosuppressive treatments, variable 
treatment practices are likely to explain some of these dif-
ferences. Similar results have been reported by the DOPPS 
investigators for patients on maintenance dialysis  [12] . 
Utilizing monitoring practices and target ranges suggest-
ed by appropriate guidelines  [19–21] , targeted continuous 
quality improvement practices and perhaps dedicated 
‘risk management clinics’ for renal transplant recipients 
may improve the quality of treatment and perhaps also 
outcomes.
 To our knowledge, this is the largest point-prevalence 
cross-sectional PTA survey ever conducted. An addition-
al strength of the study is its multicentre, multinational 
design.
 Several limitations, however, should also be consid-
ered. This cohort was a prevalent cohort which is subject 
to the problem of incidence-prevalence bias. A significant 
limitation of observational studies, such as ours, is that 
they cannot prove causal associations between predictors 
and outcomes. Our sample was a convenience sample and 
we do not claim representativeness. The non-random se-
lection of the centres participating in the survey may be 
the source of selection bias; consequently, our data may 
not be applicable to the whole RTx population without 
consideration. We did not have information about sev-
eral parameters (primary kidney disease, presence of dia-
betes, percentage of hypochromic red blood cells, trans-
ferrin saturation, serum albumin and CRP levels, comor-
bidity, panel-reactive antibodies, cold ischemic time, the 
use of drugs which effect Hb (ACE inhibitors, co-trimox-
azole, CMV prophylaxis), number of blood transfusions, 
acute rejection episodes, intact parathormone, inflam-
matory markers, donor type, immunosuppression regi-
men and ethnicity) that may be associated with anaemia 
or management practices in the participating centres. 
Another weakness of our trial is that we did not have data 
about the iron status from 43% of our patients. We do not 
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think, however, that our main findings are systematical-
ly biased because of these limitations. Finally, we note 
that the large majority of the patients in this sample (95%) 
had their transplant more than 12 months prior to data 
collection; therefore, the data present are relevant to the 
‘late’ PTA.
 In summary, we found that the prevalence and man-
agement of anaemia have not changed over the last 5 
years. PTA was present in 1 of 3 RTx patients and anaemia 
potentially requiring treatment or at least more intensive 
medical attention occurred in about 1 of 7 patients. Im-
portantly, more than two thirds of these patients have not 
received ESA treatment for their condition. However, to 
date we still do not have a prospective, randomized study 
which would assess the potential beneficial effects of 
ESAs in RTx recipients. Furthermore, substantial prac-
tice variations are seen across different transplant centres 
in their ESA use. Finally, data about iron studies are fre-
quently not done on a regular basis. We suggest that a 
more systematic approach to the detection and manage-
ment of PTA and iron status is needed to improve quality 
of care and outcomes in this patient population.
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